Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen

Benzinga Newsdesk www.benzinga.com Positive 92.4%

Neg 0% Neu 0% Pos 92.4%

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis
Fewer than 1% of patients discontinued treatment due to treatment-related events at one year
New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment

Comments

No comments yet. Be the first!